Caristo Diagnostics Gains AMA Approval for AI Heart Disease Tool

Caristo Diagnostics has achieved a significant milestone with the American Medical Association (AMA) approving new Category III CPT codes for its AI-powered CaRi-Heart technology. Announced in a press release, this approval is a crucial step towards integrating the technology into routine clinical care in the U.S.

The CaRi-Heart tool is designed to detect coronary inflammation from routine CT scans, offering a new approach to cardiac risk assessment by revealing biological drivers of heart disease. This advancement allows for proactive, AI-driven risk assessment, potentially transforming preventive cardiology by enabling earlier intervention.

The newly approved CPT codes, X409T and add-on code X434T, will be published on the AMA website by July 2025 and become effective on January 1, 2026. This approval comes ahead of the CaRi-Heart market launch schedule, supported by medical societies like the American College of Cardiology, highlighting the growing consensus on the importance of coronary inflammation as a risk factor for heart attacks.